Review of Cell Therapeutics drug delayed; GeoVax updates HIV vaccine progress;

 @FierceBiotech: Live from BIO CEO: Nile Therapeutics CEO discusses company's pipeline, plans. Article | Follow @FierceBiotech

 @JohnCFierce: Anyone notice how much more polished/careful executives become after they go public? Follow @JohnCFierce

> An FDA panel review of a Cell Therapeutics experimental lymphoma drug has been postponed due to weather. Story

> GeoVax Labs, an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today provided an update on its vaccine trials progress. Release

> San Diego-based Halozyme Therapeutics is working on a treatment that attacks cellulite at its source. Story

> British court has upheld a ruling invalidating a patent on a gene sequence held by Human Genome Sciences, handing victory in the case to Eli Lilly, which had challenged HGS's patent, lawyers familiar with the case said on Tuesday. Report

> Rhode Island's state-backed venture arm, the Slater Technology Fund, is investing $500,000 in Providence-based CytoSolv, which is developing a treatment for diabetic ulcers and other wounds. Story

> Eye-drug maker Ista Pharmaceuticals Inc. said Monday it expects to report a profit in 2010, and forecast greater sales than expected by Wall Street. Report

Pharma News

 @FiercePharma: Pfizer launches emerging-markets discounts. Report | Follow @FiercePharma

> Ever wonder why GlaxoSmithKline CEO Andrew Witty is so interested in Africa? Well, it might be that time in Johannesburg just before Nelson Mandela was elected president. Report

> The U.K.'s National Institute of Clinical Excellence has issued a new round of cancer-drug refusals. The drugs simply cost too much, NICE says. And to high prices, the cost-effectiveness watchdog always responds the way Queen Victoria did to a boorish guest: NICE is not amused. Article

> Eli Lilly CEO John Lechleiter saw a pay hike of 30% last year. Article

> AstraZeneca's Crestor has scored. The cholesterol drug can now be marketed as a preventive, not just a treatment. Article

Manufacturing News

> Ranbaxy has come up short in its responses to the FDA regarding GMP violations. A late December warning letter recently posted to the FDA Internet site says that the drug maker's "attempts to make global corrections after past regulatory actions have been inadequate." Ranbaxy article

> An anti-counterfeiting pilot project underway in Nigeria uses a cell-phone service for drug authentication. News

> While acknowledging that the global supply chain makes it impossible for FDA to "interdict everything harmful at our borders," FDA Commissioner Margaret Hamburg last week unveiled a system that will improve interdiction efforts. Article

Research News

> The drug Dimebon, which has shown some significant promise for Alzheimer's, has now registered positive results in a trial designed to test the therapy's ability to improve thinking, learning and memory skills for people who suffer from Huntington's. Dimebon article

> A pair of top scientific institutes has agreed to license out flu antibodies they designed with the CDC to Roche and its subsidiary Genentech. Report

> Most available osteoporosis treatments can only prevent the breakdown of old bone. But an investigational drug that effectively cured osteoporosis in mice and rats in a study could point the way to a new class of therapies. Article

And Finally... Scientists from the University College London in the U.K. have found that living a life of boredom can kill you. Story

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.